Nucana AI Stock Analysis
Want to see NCNA full AI Analyst Report?
Nucana (NCNA) AI Stock Analysis
Nucana
(NASDAQ:NCNA)
The overall score reflects NCNA's high-risk profile as a pre-revenue biotechnology firm. The strongest positive factor is a disciplined, virtually debt-free balance sheet with improving cash burn. However, this is heavily outweighed by structurally negative earnings, non-existent revenue, weak technical momentum with the stock trending below all major moving averages, and a speculative valuation.
Nucana (NCNA) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $5.40M
- Dividend Yield
- ―
- Average Volume (3M)
- 115.96K
- Price to Earnings (P/E)
- -0.2
- Beta (1Y)
- 1.42
- Revenue Growth
- ―
- EPS Growth
- ―
- Country
- US
- Employees
- 11
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Nucana Business Overview & Revenue Model
Company Description
NuCana plc is a clinical-stage biopharmaceutical firm dedicated to pioneering advanced therapies for oncology. Its innovative product pipeline is underpinned by a proprietary ProTide technology platform. Among its key drug candidates, Acelarin is pro...
Nucana Financial Statement Overview
Summary
The company is a pre-revenue biotech operating at a structural loss with continuous cash burn. However, it benefits from a highly conservative, virtually debt-free balance sheet and narrowing operating cash outflows.
Income Statement
30NegativeBalance Sheet
65PositiveCash Flow
40Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -140.82K | 0 | 0 | 0 | 0 | 0 |
| EBITDA | -12.49M | -20.56M | -22.48M | -30.55M | -42.98M | -44.42M |
| Net Income | -11.04M | -29.35M | -19.00M | -27.63M | -32.02M | -40.53M |
Balance Sheet | ||||||
| Total Assets | 24.58M | 29.83M | 14.77M | 27.81M | 58.25M | 77.47M |
| Cash, Cash Equivalents and Short-Term Investments | 18.47M | 24.25M | 6.75M | 17.23M | 41.91M | 60.26M |
| Total Debt | 668.45K | 676.00K | 190.00K | 396.00K | 639.00K | 371.00K |
| Total Liabilities | 4.89M | 5.51M | 8.82M | 12.92M | 19.75M | 11.93M |
| Stockholders Equity | 19.69M | 24.33M | 5.95M | 14.89M | 38.50M | 65.55M |
Cash Flow | ||||||
| Free Cash Flow | -7.89M | -7.66M | -19.41M | -26.92M | -23.68M | -24.89M |
| Operating Cash Flow | -7.76M | -7.47M | -19.12M | -26.44M | -23.16M | -23.82M |
| Investing Cash Flow | 123.24K | 159.00K | 79.00K | 2.89M | 120.00K | -3.56M |
| Financing Cash Flow | 457.48K | 25.01M | 8.18M | -53.00K | -161.00K | -98.00K |
Nucana Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NCNA, the sentiment is Negative. The current price of 0.83 is below the 20-day moving average (MA) of 0.97, below the 50-day MA of 1.11, and below the 200-day MA of 1.63, indicating a bearish trend. The MACD of -0.06 indicates Positive momentum. The RSI at 35.65 is Neutral, neither overbought nor oversold. The STOCH value of 26.09 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for NCNA.
Nucana Risk Analysis
Nucana disclosed 92 risk factors in its most recent earnings report. Nucana reported the most risks in the "Tech & Innovation" category.
Latest Risks Added
3 New RisksNucana Peers Comparison
Overall Rating
XBIO47Neutral
IMRN44Neutral
APRE43Neutral
NCNA41Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 47Neutral | $3.77M | -1.00 | -58.96% | ― | 3.50% | 22.76% | |
| 44Neutral | $8.03M | -2.87 | -31.88% | ― | 10.41% | 42.44% | |
| 43Neutral | $6.43M | -0.65 | -44.26% | ― | -99.32% | 67.31% | |
| 41Neutral | $4.29M | -0.21 | -51.04% | ― | ― | ― |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| NCNA | Nucana Plc | 0.83 | -2.73 | -76.63% | |
| XBIO | Xenetic Biosciences, Inc. | 1.53 | -0.78 | -33.77% | |
| IMRN | Immuron | 0.87 | -0.75 | -46.54% | |
| APRE | Aprea Therapeutics, Inc. | 0.45 | -0.66 | -59.19% |
Nucana Corporate Events
NuCana Announces Third-Quarter 2026 Financial Results
NuCana plc is a foreign issuer with principal executive offices in Edinburgh, United Kingdom. On November 12, 2026, the company issued a press release announcing its third-quarter 2026 financial results, including unaudited condensed consolidated fin...
NuCana Wins Key European Patent for Lead Cancer Drug NUC-7738
NuCana plc, a clinical-stage biopharmaceutical company based in Edinburgh, develops cancer therapies using its proprietary ProTide technology to enhance existing nucleoside analog chemotherapy agents. Its lead candidates include NUC-7738, a novel ant...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 15, 2026
